

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

PROPOSED CHANGE OF COMPANY NAME

PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the current English name of the Company from “Kaisa Health Group Holdings Limited” to “Qinghai Pharmaceutical Group Limited” and to adopt “青海製藥集團有限公司” as its secondary name in Chinese in place of the current Chinese secondary name of “佳兆業健康集團控股有限公司”. The Proposed Change of Company Name is subject to the satisfaction of the conditions as set out in the paragraph headed “Conditions of the Proposed Change of Company Name” below.

GENERAL

A SGM will be convened and held by the Company for the Shareholders to consider and, if thought fit, pass a special resolution regarding the Proposed Change of Company Name.

A circular containing, among other things, further information regarding (1) the Proposed Change of Company Name and (2) a notice of the SGM and the related form of proxy, will be despatched to the Shareholders as soon as practicable.

PROPOSED CHANGE OF COMPANY NAME

The Board of Directors of Kaisa Health Group Holdings Limited proposes to change the current English name of the Company from “Kaisa Health Group Holdings Limited” to “Qinghai Pharmaceutical Group Limited” and to adopt “青海製藥集團有限公司” as its secondary name in Chinese in place of the current Chinese secondary name of “佳兆業健康集團控股有限公司”.

CONDITIONS OF THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name is subject to the satisfaction of the following conditions:

- (i) the passing of a special resolution by the Shareholders approving the Proposed Change of Company Name at the SGM; and
- (ii) the Registrar granting approval of the Proposed Change of Company Name by way of issuing a Certificate of Change of Name and a Certificate of Secondary Name.

Subject to the satisfaction of the conditions set out above, the Proposed Change of Company Name will take effect from the date on which the Registrar enters the new English name of the Company in place of the current English name of the Company and the new secondary name in Chinese of the Company in place of the current secondary name into the register of companies maintained by the Registrar. The Company will then carry out all necessary registration and/or filing procedures with the Companies Registry in Hong Kong.

REASONS FOR THE PROPOSED CHANGE OF COMPANY NAME

The Company and its subsidiaries are principally engaged in the dental business including the sale and production and research and development of dental prosthetics and trading of dental implant instruments, and healthcare business including provision of public health and medical services. As disclosed in the Company's announcement dated 18 March 2026 and circular dated 2 June 2026 ("**Acquisition Circular**"), the Company proposes to acquire ("**Acquisition**") an interest in a pharmaceutical business conducted by 青海製藥有限公司 (Qinghai Pharmaceutical Co. Ltd.*), which, including its predecessor, has a long history business of over 60 years in the healthcare field. For further details about the reasons and benefits of the Acquisition, please refer to the section headed "Reasons for and benefits of the Acquisition" in the Acquisition Circular. The Proposed Change of Company Name will provide a new corporate image for the Company and in light of the long business history of the business under the Acquisition, the Proposed Change of Company Name is expected to enhance the Group's overall brand value thereby increasing market competitiveness. The Board therefore believes that the Proposed Change of Company Name is in the interests of the Company and its Shareholders as a whole.

* *The English translation of the Chinese name is included for information purposes only and should not be regarded as their official English translation.*

EFFECTS OF THE PROPOSED CHANGE OF COMPANY NAME

The Proposed Change of Company Name will not affect any rights of the Shareholders and the trading of the Shares on the Stock Exchange or the daily business operations of the Company and its financial position. All existing share certificates of the Company in issue bearing the existing name of the Company will, after the Proposed Change of Company Name becomes effective, continue to be effective and as prima facie evidence of legal title to the Shares and will continue to be valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates bearing the new name of the Company. Upon the Proposed Change of Company Name becoming effective, any new share certificate of the Company will be issued in the new name of the Company.

In addition, subject to the confirmation by the Stock Exchange, the English and Chinese stock short names of the Company for trading of the Shares on the Stock Exchange will be changed after the Proposed Change of Company Name becomes effective, and the Company will also adopt a new logo.

Further announcement(s) will be made by the Company to inform the Shareholders of the results of the SGM, the effective date of the Proposed Change of Company Name, the new English and Chinese stock short names of the Company for trading of the Shares on the Stock Exchange, the new company logo of the Company, the new website address of the Company and other relevant information as and when appropriate.

GENERAL

A SGM will be convened and held by the Company for the Shareholders to consider and, if thought fit, pass a special resolution regarding the Proposed Change of Company Name.

A circular containing, among other things, further information regarding (1) the Proposed Change of Company Name and (2) a notice of the SGM and the related form of proxy, will be despatched to the Shareholders as soon as practicable.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“Board”	the Board of Directors of the Company
“Company”	Kaisa Health Group Holdings Limited (佳兆業健康集團控股有限公司), a company incorporated under the laws of Bermuda with limited liability and the Shares of which are listed and traded on the Main Board of the Stock Exchange (Stock Code: 876)

“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries from time to time
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China, and for the purpose of this announcement only, excludes Hong Kong, the Macao Special Administrative Region of the PRC and Taiwan
“Proposed Change of Company Name”	the change of the current English name of the Company of “Kaisa Health Group Holdings Limited” to “Qinghai Pharmaceutical Group Limited” and adoption of “青海製藥集團有限公司” as the Company’s secondary name in Chinese in place of the current Chinese secondary name of “佳兆業健康集團控股有限公司”
“Registrar”	Registrar of Companies in Bermuda
“SGM”	the special general meeting of the Company to be convened for the purpose of considering, and if thought fit, approving the Proposed Change of Company Name
“Share(s)”	ordinary share(s) of par value of HK\$0.0625 each in the issued share capital of the Company
“Shareholder(s)”	the holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman and Executive Director

Hong Kong, 15 July 2026

As at the date of this announcement, the Board comprises six executive Directors, namely Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Ms. Luo Tingting, Mr. Xie Binhong, Mr. Yang Feng and Mr. Ye Haoda and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying.